Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hydrocortisone Acetate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: Hydrocortisone Acetate. Displaying page 1 of 1.
    EudraCT Number: 2010-019178-33 Sponsor Protocol Number: BRD/10/1-L Start Date*: 2010-05-27
    Sponsor Name:CHU de Nantes
    Full Title: Traitement de l'insuffisance surrénale secondaire à un traumatisme crânien grave. Etude multicentrique, contrôlée, randomisée portant sur un médicament. - Etude Corti-TC"
    Medical condition: Insuffisance surrénale secondaire à un traumatisme crânien grave
    Disease: Version SOC Term Classification Code Term Level
    12.1 10052382 Secondary adrenal insufficiency LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2005-002471-32 Sponsor Protocol Number: S173-GB-01 Start Date*: Information not available in EudraCT
    Sponsor Name:Stiefel Laboratories Maidenhead Ltd (commonly known as Stiefel International R&D)
    Full Title: A PHASE II, SINGLE-CENTRE, INVESTIGATOR-BLIND, PARALLEL GROUP CLINICAL TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF 1% CICLOPIROX OLAMINE (BATRAFEN® CREAM), COMPARED TO 1% HYDROCORTISONE ACETATE...
    Medical condition: Mild to moderate atopic eczema
    Disease: Version SOC Term Classification Code Term Level
    8.0 10003641 LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-004028-12 Sponsor Protocol Number: PLEN2013 Start Date*: 2014-05-13
    Sponsor Name:Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Full Title: Replacement therapy with modified-release hydrocortisone (Plenadren) in patients with central adrenal insufficiency
    Medical condition: Central hypoadrenalism
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004860 10020936 Hypoadrenalism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-003734-34 Sponsor Protocol Number: BT0800BEL001 Start Date*: 2005-03-03
    Sponsor Name:Barrier Therapeutics nv
    Full Title: A one-weel, randomized, double-blind, placebo-controlled pilot trial to evaluate oral R129160 (60 mg b.i.d.) on the alleviation of itch in atopic dermatitis patients
    Medical condition: Atopic Dermatitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Ongoing) CZ (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003596-19 Sponsor Protocol Number: CHS1221 Start Date*: 2020-07-29
    Sponsor Name:Cristcot HCA LLC
    Full Title: A Three-Arm, Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Safety and Efficacy of Once-Daily and Twice-Daily Dosing of a Novel Hydrocortisone Acetate 90 mg Suppository ...
    Medical condition: Ulcerative Colitis of the Rectum
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    20.0 10017947 - Gastrointestinal disorders 10009900 Colitis ulcerative PT
    20.0 10021428 - Immune system disorders 10027682 Immune and associated conditions NEC HLT
    20.0 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    20.0 10021428 - Immune system disorders 10027665 Immune disorders NEC HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) IT (Ongoing) RO (Ongoing) DK (Ongoing) BG (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001175-38 Sponsor Protocol Number: 6520-9170-08 Start Date*: 2012-01-13
    Sponsor Name:MEDICE Arzneimittel Pütter GmbH & CO.KG
    Full Title: A multi-center, randomized, double-blind,phase II trial with intraindividual comparison to assess superiority of Soventol HydroCort 0.5 % Cremogel vs vehicle on lesional skin in patients with mild ...
    Medical condition: manifest atopic dermatitis diagnosed according to Hanifin and Rajka, or seborrheic eczema or stasis dermatitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-004485-40 Sponsor Protocol Number: P070128 Start Date*: 2008-01-30
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Etude prospective, multicentrique contrôlée vs placebo, randomisée, en double insu comparant la protéine C activée, les faibles doses de corticoïdes et leur association dans le traitement du choc s...
    Medical condition: Choc septique
    Disease: Version SOC Term Classification Code Term Level
    8.1 10040580 Choc septique PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004759-39 Sponsor Protocol Number: 06-02/Nyco-P Start Date*: 2007-11-26
    Sponsor Name:Dermapharm AG
    Full Title: Doppelblinde, randomisierte klinische Studie zum Vergleich der Wirksamkeit und Verträglichkeit einer Nystatin (100 000 I.E./g)/Hydrocortisonacetat (5 mg/g) -haltigen Paste vs. einer Nystatin (100 0...
    Medical condition: Adult patients with moderate to severe inflamed candidiasis of the skin
    Disease: Version SOC Term Classification Code Term Level
    8.1 10040809 Skin candida NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004542-28 Sponsor Protocol Number: NL59862.091.16 Start Date*: 2017-09-14
    Sponsor Name:Radboud University Medical Center
    Full Title: A randomized controlled pilot study comparing the efficacy of topical coal tar to topical corticosteroids in children aged 1 to < 16 years with moderate-severe atopic dermatitis.
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-003900-28 Sponsor Protocol Number: TOFA-PREDICT Start Date*: 2018-04-04
    Sponsor Name:UMC Utrecht
    Full Title: A Stratification trial to determine key immunological factors predicting Tofacitinib efficacy in Psoriatic Arthritis (PsA). TOFA-PREDICT
    Medical condition: psoriatic arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003024-20 Sponsor Protocol Number: HEMP-0119/ES Start Date*: 2019-10-15
    Sponsor Name:FAES FARMA SA
    Full Title: Multicenter, double-blind, randomized clinical trial to evaluate and compare the efficacy and safety of Hemorrane® Plus (Hemorrane® + benzocaine) with Hemorrane® and with placebo in patients with g...
    Medical condition: Bleeding grade I hemorrhoids
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-005066-32 Sponsor Protocol Number: 80-82310-98-09036 Start Date*: 2009-02-03
    Sponsor Name:University Medical Center
    Full Title: Comparison of ototopical antibiotic-steroid drops or oral antibiotics versus watchful waiting in children with acute tympanostomy tube otorrhea
    Medical condition: Acute tympanostomy tube otorrhea in children
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033099 Otorrhea LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-004765-40 Sponsor Protocol Number: SPR001-204 Start Date*: 2020-11-17
    Sponsor Name:Spruce Biosciences, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Co...
    Medical condition: Classic Congenital Adrenal Hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10010323 Congenital adrenal hyperplasia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) NL (Trial now transitioned) DE (Ongoing) SE (Trial now transitioned) PL (Trial now transitioned) LT (Trial now transitioned) IT (Ongoing) EE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001438-46 Sponsor Protocol Number: A3921104 Start Date*: 2018-03-27
    Sponsor Name:Pfizer Inc.
    Full Title: EFFICACY, SAFETY AND TOLERABILITY OF TOFACITINIB FOR TREATMENT OF POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS (JIA) IN CHILDREN AND ADOLESCENT SUBJECTS
    Medical condition: JUVENILE IDIOPATHIC ARTHRITIS (JIA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-000839-17 Sponsor Protocol Number: CASM981C2439 Start Date*: 2005-04-11
    Sponsor Name:NOVARTIS FARMA
    Full Title: A 16-week, randomized, multi-center, parallel-group, pimecrolimus-blinded, controlled study (4-week treatment period followed by 12-week observational period) to evaluate the safety of concomitant ...
    Medical condition: Treatment of severe atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    6.1 10012438 PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-004764-22 Sponsor Protocol Number: SPR001-203 Start Date*: 2020-10-15
    Sponsor Name:Spruce Biosciences, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects with Classic Congenital Adrenal Hyperplasia
    Medical condition: Classic Congenital Adrenal Hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10010323 Congenital adrenal hyperplasia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) SE (Trial now transitioned) DE (Ongoing) DK (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) IT (Ongoing) LT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000984-34 Sponsor Protocol Number: 6630-9170-917016 Start Date*: 2018-05-24
    Sponsor Name:Medice Arzneimittel Pütter GmbH & Co KG
    Full Title: A multi-center, randomized, double-blind, phase II trial with intraindividual comparison to assess superiority of Soventol HydroCortisonACETAT 1 % Cremogel versus vehicle on lesional skin in patien...
    Medical condition: atopic dermatitis, seborrheic eczema or stasis dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10003639 Atopic dermatitis LLT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10062813 Seborrheic eczema LLT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10041955 Stasis dermatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 21:44:57 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA